Bausch + Lomb

Company snapshot

Bausch + Lomb is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people’s eyesight. Our core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehens

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 25 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Bausch + Lomb. Not investment advice.

• deal Jun 11, 2026

  AstraZeneca expands obesity push as it invests $125M in ultrasound medicine

Recent activity

Latest pipeline, patent, and corporate events for Bausch + Lomb.

1. Jun 8, 2026 Clinical update

   0.59 mg fluocinolone acetonide intravitreal implant — Phase 2

2. May 26, 2026 Clinical update

   Duobrii — Phase 2

3. May 26, 2026 Clinical update

   Bryhali — Phase 2

4. Oct 29, 2020 Patent grant

   GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF

5. Jul 30, 2020 Patent grant

   CROSSLINKED POLYMERIC NETWORK AND USE THEREOF

View all clinical trial activity →

• What is Bausch + Lomb?

  Bausch & Lomb is a pharma organization headquartered in Rochester, US. Primary therapeutic focus areas include Plaque Psoriasis, Diabetic Macular Edema. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Clin

• Is Bausch + Lomb publicly traded?

  Bausch + Lomb appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Bausch + Lomb develop or market?

  We link 5 drug profile(s) where Bausch + Lomb is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bausch-health-ireland-limited#company-drugs.

• What are the latest developments for Bausch + Lomb?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Bausch + Lomb focus on?

  Bausch + Lomb focuses on Plaque Psoriasis, Diabetic Macular Edema based on our analysis of their pipeline programs and drug development activities.